Savara Inc. (SVRA)
2.99
0.27 (9.93%)
At close: Jan 15, 2025, 1:21 PM
Company Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases.
Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
The company is headquartered in Austin, Texas.
Savara Inc.
| Country | United States |
| IPO Date | Apr 28, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 37 |
| CEO | Matthew Pauls J.D., M.B.A. |
Contact Details
Address: Building III Austin, Texas United States | |
| Website | https://www.savarapharma.com |
Stock Details
| Ticker Symbol | SVRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001160308 |
| CUSIP Number | 805111101 |
| ISIN Number | US8051111016 |
| Employer ID | 84-1318182 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Matthew Pauls J.D., M.B.A. | Chairman & Chief Executive Officer |
| David L. Lowrance CPA | Chief Financial Officer, Chief Administrative Officer & Secretary |
| Robert Lutz M.B.A. | Chief Operating Officer |
| Anne Erickson | Chief Business Officer |
| Brian Maurer | Head of Clinical Operations |
| Charles LaPree | Senior Vice President of Global Regulatory Affairs & Quality Assurance |
| Dr. Peter Clarke Ph.D. | Executive Vice President of Global Technical Operations |
| Dr. Raymond Dennis Pratt FACP, M.D. | Chief Medical Officer |
| Kate McCabe J.D. | Senior Vice President & General Counsel |
| Scott L. Wilhoit | Executive Vice President of Global Commercial |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 13, 2025 | 8-K | Current Report |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |
| Dec 16, 2024 | 4 | Filing |